US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ImageneBio, Inc.

5.78

+0.13002.30%

Post-market: 5.780.00000.00%18:00 EDT

Volume:62.29K

Turnover:355.25K

Market Cap:64.63M

PE:-0.60

High:5.88

Open:5.60

Low:5.52

Close:5.65

52wk High:18.00

52wk Low:3.94

Shares:11.18M

Float Shares:6.20M

Volume Ratio:0.02

T/O Rate:1.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.6449

EPS(LYR):-9.6449

ROE:-68.91%

ROA:-35.86%

PB:0.49

PE(LYR):-0.60

Loading ...

Overview Company News Filings

ImageneBio files Form 3 as director Su Wei-guo reports no holdings

Top Midday Gainers

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

ImageneBio prices USD 30 million private placement of pre-funded warrants

Imagenebio Inc - Proceeds to Support Img-007 Development in Alopecia Areata and Atopic Dermatitis

THOMSON REUTERS

Imagenebio Announces $30 Million Private Placement

THOMSON REUTERS

Press Release: ImageneBio Announces $30 Million Private Placement

American Tungsten Extends Mineralized Strike at Idaho IMA Mine With Strong Drill Results

NH Investment & Securities' Solid Capitalization Anchors Corporate Financing Expansion, S&P Says

MT Newswires Live

ImageneBio names Bob Lally principal accounting officer as Erin Butler exits

ImageneBio grants 43,000 stock options at USD 6.20 per share under its 2025 Inducement Plan

Imagenebio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanobiotix (NBTX), ImageneBio (IMA) and Dianthus Therapeutics (DNTH)

Legal and Regulatory Risks: How Litigation and Government Actions Could Impact Imagenebio, Inc.’s Financial Performance

Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA)

ImageneBio Q4 EPS $(6.73) Misses $(1.44) Estimate

ImageneBio Q4 net loss rose 44% to USD 6.9 million

Press Release: ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

ImageneBio Inc expected to post a loss of $1.45 a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMA\",,,,,undefined,":{"symbol":"IMA","market":"US","secType":"STK","nameCN":"ImageneBio, Inc.","latestPrice":5.78,"timestamp":1776369600000,"preClose":5.65,"halted":0,"volume":62293,"hourTrading":{"tag":"盘后","latestPrice":5.78,"preClose":5.78,"latestTime":"18:00 EDT","volume":24,"amount":137.26,"timestamp":1776376840285,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.023008849557522103,"floatShares":6199299,"shares":11181700,"eps":-9.64492,"marketStatus":"Not Yet Opened","change":0.13,"latestTime":"04-16 16:00:00 EDT","open":5.6,"high":5.88,"low":5.5225,"amount":355254.57449020003,"amplitude":0.063274,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.64492,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776412800000},"marketStatusCode":0,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":5.65,"preHourTrading":{"tag":"盘前","latestPrice":5.53,"preClose":5.65,"latestTime":"09:25 EDT","volume":3670,"amount":19933.342227999998,"timestamp":1776345949297,"change":-0.12,"changeRate":-0.021239,"amplitude":0.053097},"postHourTrading":{"tag":"盘后","latestPrice":5.78,"preClose":5.78,"latestTime":"18:00 EDT","volume":24,"amount":137.26,"timestamp":1776376840285,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.015988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMA\",,,,,undefined,":{"symbol":"IMA","floatShares":6199299,"roa":"-35.86%","roe":"-68.91%","lyrEps":-9.64492,"volumeRatio":0.015988,"shares":11181700,"dividePrice":0,"high":5.88,"amplitude":0.063274,"preClose":5.65,"low":5.5225,"week52Low":3.94,"pbRate":"0.49","psRate":"80.79","week52High":18,"institutionHeld":0,"latestPrice":5.78,"eps":-9.64492,"divideRate":0,"volume":62293,"delay":0,"ttmEps":-9.64492,"open":5.6,"prevYearClose":6.9,"prevWeekClose":4.9018,"prevMonthClose":5,"prevQuarterClose":5,"fiveDayClose":4.75,"twentyDayClose":5.825,"sixtyDayClose":6.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMA\",params:#limit:5,,,undefined,":[{"date":"2026-03-10","symbol":"IMA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1773129600000,"name":null,"time":"Pre-Market","dateTimestamp":1773115200000,"actualEps":null},{"market":"US","date":"2025-11-12","symbol":"IMA","fiscalQuarterEnding":"2025/09","expectedEps":-1.47,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-2.91},{"market":"US","date":"2025-07-28","symbol":"IMA","defaultRemindTime":1753709400000,"type":"split","dateTimestamp":1753675200000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-07-24","symbol":"IMA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1753329600000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-05-08","symbol":"IMA","fiscalQuarterEnding":"2025/03","expectedEps":-0.21,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0,"hold":0,"sell":0,"strongSell":0.3333,"meanLabel":"BUY","meanPercent":0,"analysts":3,"updateTime":1764129600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMA","date":"2026-04-15","current":-0.599279,"percent":0.905882,"low":-8.134224,"twenty":-4.362798,"median":-1.748359,"eighty":-1.521811,"high":-1.122224,"avg":-2.99979,"sd":1.95976,"marketCap":64090021},"quantilePoints":[{"date":"2025-08-15","current":-8.134224,"twenty":-8.112228,"median":-8.06823,"eighty":-8.016532,"marketCap":165376899},{"date":"2025-08-22","current":-7.269609,"twenty":-8.089126,"median":-7.938985,"eighty":-7.265478,"marketCap":157437913},{"date":"2025-08-29","current":-6.949498,"twenty":-8.071529,"median":-7.347055,"eighty":-7.207651,"marketCap":150505278},{"date":"2025-09-05","current":-4.362798,"twenty":-8.06823,"median":-7.269609,"eighty":-7.002161,"marketCap":94485111},{"date":"2025-09-12","current":-4.750028,"twenty":-7.913135,"median":-7.165056,"eighty":-4.777909,"marketCap":102871364},{"date":"2025-09-19","current":-4.311167,"twenty":-7.809737,"median":-7.03727,"eighty":-4.615789,"marketCap":93366944},{"date":"2025-09-26","current":-4.016872,"twenty":-7.532127,"median":-6.908193,"eighty":-4.311167,"marketCap":86993392},{"date":"2025-10-03","current":-4.460896,"twenty":-7.322272,"median":-4.750028,"eighty":-4.238884,"marketCap":96609628},{"date":"2025-10-10","current":-4.24921,"twenty":-7.284065,"median":-4.672583,"eighty":-4.255406,"marketCap":92025144},{"date":"2025-10-17","current":-3.918773,"twenty":-7.257217,"median":-4.460896,"eighty":-4.122198,"marketCap":84868875},{"date":"2025-10-24","current":-3.815512,"twenty":-7.248956,"median":-4.418301,"eighty":-4.002415,"marketCap":82632541},{"date":"2025-10-31","current":-4.336982,"twenty":-7.148276,"median":-4.396358,"eighty":-4.069535,"marketCap":93926028},{"date":"2025-11-07","current":-4.331819,"twenty":-7.057922,"median":-4.378287,"eighty":-4.107742,"marketCap":93814211},{"date":"2025-11-14","current":-4.300841,"twenty":-7.039335,"median":-4.362798,"eighty":-4.109807,"marketCap":93143311},{"date":"2025-11-21","current":-1.760672,"twenty":-6.984607,"median":-4.334401,"eighty":-3.978665,"marketCap":76154335},{"date":"2025-11-28","current":-1.69911,"twenty":-6.937107,"median":-4.311167,"eighty":-3.941491,"marketCap":73491596},{"date":"2025-12-05","current":-1.66956,"twenty":-6.910259,"median":-4.306004,"eighty":-3.874371,"marketCap":72213481},{"date":"2025-12-12","current":-1.593223,"twenty":-6.057319,"median":-4.275025,"eighty":-1.94191,"marketCap":68911685},{"date":"2025-12-19","current":-1.524274,"twenty":-4.777909,"median":-4.254373,"eighty":-1.770522,"marketCap":65929417},{"date":"2025-12-26","current":-1.44055,"twenty":-4.748995,"median":-4.244047,"eighty":-1.699602,"marketCap":62308092},{"date":"2026-01-02","current":-1.69911,"twenty":-4.744865,"median":-4.207906,"eighty":-1.69911,"marketCap":73491596},{"date":"2026-01-09","current":-1.686797,"twenty":-4.71905,"median":-4.130459,"eighty":-1.664635,"marketCap":72959048},{"date":"2026-01-16","current":-1.62031,"twenty":-4.626115,"median":-4.109807,"eighty":-1.664635,"marketCap":70083290},{"date":"2026-01-23","current":-1.740972,"twenty":-4.605462,"median":-4.016872,"eighty":-1.646413,"marketCap":75302258},{"date":"2026-01-30","current":-1.803765,"twenty":-4.550733,"median":-3.972986,"eighty":-1.66168,"marketCap":78018252},{"date":"2026-02-06","current":-1.726197,"twenty":-4.505299,"median":-3.939426,"eighty":-1.666605,"marketCap":74663201},{"date":"2026-02-13","current":-1.686797,"twenty":-4.492908,"median":-3.903284,"eighty":-1.667098,"marketCap":72959048},{"date":"2026-02-20","current":-1.64986,"twenty":-4.473288,"median":-3.838746,"eighty":-1.658725,"marketCap":71361405},{"date":"2026-02-27","current":-1.681872,"twenty":-4.451603,"median":-2.010613,"eighty":-1.64986,"marketCap":72746029},{"date":"2026-03-06","current":-1.487337,"twenty":-4.445407,"median":-1.864096,"eighty":-1.631638,"marketCap":64331774},{"date":"2026-03-13","current":-1.479416,"twenty":-4.442309,"median":-1.812384,"eighty":-1.610461,"marketCap":67090032},{"date":"2026-03-20","current":-1.403396,"twenty":-4.424754,"median":-1.804381,"eighty":-1.602088,"marketCap":63642621},{"date":"2026-03-27","current":-1.33187,"twenty":-4.403586,"median":-1.785297,"eighty":-1.581403,"marketCap":60398973},{"date":"2026-04-02","current":-1.245545,"twenty":-4.395325,"median":-1.760672,"eighty":-1.558256,"marketCap":56484224},{"date":"2026-04-10","current":-1.171552,"twenty":-4.381385,"median":-1.750822,"eighty":-1.52919,"marketCap":53128726},{"date":"2026-04-15","current":-1.413262,"twenty":-4.362798,"median":-1.748359,"eighty":-1.521811,"marketCap":64090021}],"updateTime":1776384878378},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628240563","title":"ImageneBio files Form 3 as director Su Wei-guo reports no holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2628240563","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628240563?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:55","pubTimestamp":1776383756,"startTime":"0","endTime":"0","summary":"ImageneBio filed an initial Form 3 naming Su Wei-guo as a director on April 16, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImageneBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL8t43DN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627145026","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2627145026","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627145026?lang=en_us&edition=fundamental","pubTime":"2026-04-14 02:19","pubTimestamp":1776104350,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  shares soared 29% after the company said Monday its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its key targets in a phase 2 trial.Over 4.10 million shares traded intraday, versus a daily average of roughly 747,000.ImageneBio  reported Monday that its private placement with certain institutional investors is expected to result in gross proceeds of about $30 million to the company.Shares jumped 22%, with intraday trading volume catapulting to more than 17.5 million from a daily average of about 38,000.Price: 65.06, Change: +13.77, Percent Change: +26.85","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","SYRE","BK4139","IMA","IMA.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627450630","title":"BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune","url":"https://stock-news.laohu8.com/highlight/detail?id=2627450630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627450630?lang=en_us&edition=fundamental","pubTime":"2026-04-14 01:50","pubTimestamp":1776102619,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, ReplimuneWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL6N40W0LU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","RIOT","ORCL","META","GPRO","GFL","PINS","SYRE","NEM","BIIB","HPE","NOW","ALLO","HP","HUT","ANIP","DOW","AVT","DAL","DVN","DIOD","APP","OCUL","IMA","CRM","SBUX","APTV","ADBE","TFX","HL","IBM","RVMD","UAL","KYMR","LEG","MARA","IDYA","CVX","SNDK","XOM","COIN","GOOGL","BBY","CAG","EMN","OXY","REPL","LYB","LUV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627144454","title":"BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627144454","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627144454?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:43","pubTimestamp":1776095026,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-SonomaWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL6N40W0Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","ADBE","ANIP","EMN","RVMD","PINS","KYMR","CDE","HUT","CAG","NEM","HPE","MARA","META","TFX","LEG","IMA","SBU","REPL","UAL","LUV","CVX","SYRE","COIN","DVN","AAL","IBM","OXY","RIOT","OCUL","SNDK","HL","DAL","GPRO","XOM","APTV","DOW","LYB","WSM","DIOD","OWL","BBY","GOOGL","SBUX","AVT","CRWV","BIIB","HTFL","ALLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627432152","title":"ImageneBio prices USD 30 million private placement of pre-funded warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2627432152","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627432152?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:03","pubTimestamp":1776078217,"startTime":"0","endTime":"0","summary":"ImageneBio entered securities purchase agreement for private placement expected to raise about USD 30 million in gross proceeds.Offering consists of pre-funded warrants to buy up to 5,770,335 common shares priced at USD 5.2 each.Warrants carry exercise price of USD 0.001 per share.Proceeds earmarked for development of IMG-007 in alopecia areata, late-stage work in atopic dermatitis.Placement led by Coastlands Capital; Leerink Partners acting as sole placement agent.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL74t8qV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4112","SG9999014005.SGD","IMA","SG9999014039.USD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4207","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","SG9999014013.SGD","MNSH","SG9999014021.USD","BK4007","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627432960","title":"Imagenebio Inc - Proceeds to Support Img-007 Development in Alopecia Areata and Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2627432960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627432960?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUA8Z60LM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627432675","title":"Imagenebio Announces $30 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627432675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627432675?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUA8Z60LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627432926","title":"Press Release: ImageneBio Announces $30 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627432926","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627432926?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:00","pubTimestamp":1776078000,"startTime":"0","endTime":"0","summary":"Private placement led by Coastlands Capital with participation. SAN DIEGO, April 13, 2026  -- ImageneBio, Inc.  today announced it has entered into a definitive securities purchase agreement with certain institutional investors in a private placement that is expected to result in gross proceeds of approximately $30 million to Imagene, before deducting placement agent fees and other expenses. The company intends to use the proceeds from the offering to support further development of IMG-007 in alopecia areata and late-stage development activities in atopic dermatitis.Pursuant to the terms of the securities purchase agreement, Imagene is selling pre-funded warrants to purchase up to 5,770,335 shares of common stock at a price of $5.199 per pre-funded warrant. The pre-funded warrants will have an exercise price of $0.001 per share.Leerink Partners is acting as sole placement agent for the private placement.The securities offered in this private placement, including the shares underlying t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622074054","title":"American Tungsten Extends Mineralized Strike at Idaho IMA Mine With Strong Drill Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074054","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074054?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:14","pubTimestamp":1774448082,"startTime":"0","endTime":"0","summary":"An announcement from Demesne Resources Ltd. ( ($TSE:TUNG) ) is now available. American Tungsten Corp. reported initial results from the second dril...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/american-tungsten-extends-mineralized-strike-at-idaho-ima-mine-with-strong-drill-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/american-tungsten-extends-mineralized-strike-at-idaho-ima-mine-with-strong-drill-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4107","IMA","BK4007","BK4117","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620248631","title":"NH Investment & Securities' Solid Capitalization Anchors Corporate Financing Expansion, S&P Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2620248631","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620248631?lang=en_us&edition=fundamental","pubTime":"2026-03-19 16:38","pubTimestamp":1773909522,"startTime":"0","endTime":"0","summary":"NH Investment & Securities'  sufficient capital will anchor growth in corporate financing, especially with its investment management account  segment gaining regulatory consent, S&P Global Ratings said in a recent release.The expansion adheres to parent NongHyup Financial Group's pivot to the corporate segment in line with the Korean government's economic growth efforts, S&P said.The parent group is strongly committed to extend support to the subsidiary in case of need, the rating agency said.The company's risk-adjusted capital ratio will drop to about 8.7% over the next two years from an estimated 9.5% in 2025, given growth in risky equities or funds following the IMA adoption, S&P said.However, the figure remains above the 7% threshold for adequate capital and earnings assessment, with S&P expecting the ratio to remain at about 7.3% even with IMA funding reaching up to 100% of shareholders' equity.The company's diversified business structure across several segments and group support ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IMA.AU","IMA","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620033064","title":"ImageneBio names Bob Lally principal accounting officer as Erin Butler exits","url":"https://stock-news.laohu8.com/highlight/detail?id=2620033064","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620033064?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:33","pubTimestamp":1773779625,"startTime":"0","endTime":"0","summary":"ImageneBio said Erin Butler, Senior Vice President, Finance & Administration and Principal Accounting Officer, will separate from the company effective March 20, 2026. Bob Lally, Senior Vice President, Finance & Operations, was appointed Principal Accounting Officer effective the same date. Lally has served in his current role since July 2025 and previously held senior finance and operations roles at Ikena Oncology, Prevail Therapeutics, and Arsanis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImageneBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbNT3M4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0001KFT4U8.USD","ELIL","LU0114720955.EUR","LU0708995401.HKD","LU2089283258.USD","LU1712237335.SGD","LU2112291526.USD","LU1868836757.USD","LU1551013425.SGD","LU2417539215.USD","LU2211815571.USD","LU1868836591.USD","LU2168564065.EUR","LU2468319806.SGD","LU2324357040.USD","LU1814569148.SGD","LU2756315318.SGD","LU1629891620.HKD","IMA","LU0256863811.USD","LU2265009873.SGD","LU2491049909.HKD","LU0096364046.USD","LU2168563687.JPY","LU2552382132.HKD","SG9999014906.USD","SG9999014914.USD","LU0672654240.SGD","SG9999018865.SGD","LU0109391861.USD","IE00BFSS7M15.SGD","LU2361045086.USD","LU0820562030.AUD","LU1064131342.USD","LU0354030511.USD","GB00BDT5M118.USD","LU0683600562.USD","LU2237443978.SGD","LU2552382058.USD","LU1720051017.SGD","LU2023251221.USD","LU1023059063.AUD","IE00B7KXQ091.USD","LU2360106947.USD","LU0882574055.USD","LU0079474960.USD","LU0964807845.USD","LU2471134523.USD","IE00BJLML261.HKD","LU2602419157.SGD","LU0061475181.USD","LU2471134879.HKD","LU0106261372.USD","LU0471298694.HKD","SG9999015986.USD","LU2456880835.USD","BK4581","LU2106854487.HKD","LU1868837300.USD","SGXZ81514606.USD","IE00BFSS8Q28.SGD","LU1989771016.USD","LU2896262040.SGD","LU1720051108.HKD","LU0943347566.SGD","IE00B1XK9C88.USD","LU1917777945.USD","LU2361044949.HKD","SGXZ31699556.SGD","LLYX","LU0353189763.USD","LU2361044865.SGD","LU1232071149.USD","LU0820561909.HKD","LU2168564495.EUR","LU2750360997.AUD","BK4599","LU0289739699.SGD","LU0323591593.USD","LU0417517546.SGD","LU2168564222.USD","LU0889565916.HKD","LU2552382215.SGD","IE00BJJMRX11.SGD","IE00BJJMRY28.SGD","LU0432979614.USD","LU1093756168.USD","LU0094547139.USD","LU1623119135.USD","IE00B1BXHZ80.USD","LU0354030438.USD","LU0466842654.USD","LU2271345857.HKD","LU2491050071.SGD","IE00BJT1NW94.SGD","IE00BK4W5L77.USD","LU0203201768.USD","LU2237443549.SGD","BK4588","LU1548497426.USD","BK4585","LU2756315664.SGD","ELIS","SG9999017495.SGD","IE00BKDWB100.SGD","LU0689472784.USD","LU0823416689.USD","BK4007","IE00B775H168.HKD","LU0225283273.USD","LU1145028129.USD","BK4516","LU0471298777.SGD","BK4533","LU1551013342.USD","SG9999014898.SGD","LU0256863902.USD","LLYZ","LU1267930730.SGD","SG9999001176.USD","LU2461242641.AUD","LU0823434740.USD","BK4534","LU1804176565.USD","IE00BJJMRZ35.SGD","IE0004445239.USD","LU0198837287.USD","SG9999014880.SGD","LU2213496289.HKD","IE00B4JS1V06.HKD","LU0456855351.SGD","LU0820561818.USD","LU0823434583.USD","LU0097036916.USD","LU2111349929.HKD","LU0266013472.USD","LU1366192091.USD","LU0316494557.USD","IE0002141913.USD","LU2750360641.GBP","SG9999015952.SGD","LU2168564149.EUR","LU2087625088.SGD","LU2237443895.HKD","LU2746668461.USD","SG9999013999.USD","LU1035775433.USD","LU1057294990.SGD","LU2089984988.USD","LU0238689110.USD","IE00B4R5TH58.HKD","LU1868836914.USD","LU1127390331.HKD","LU2108987350.USD","LU0320765992.SGD","LU2491050154.USD","LU1291159041.SGD","LU0234572021.USD","IE0004445015.USD","LU2237443382.USD","LU0006306889.USD","LU0210536198.USD","SG9999018857.SGD","LU0109394709.USD","LU0203202063.USD","LU2023250330.USD","LU0353189680.USD","SG9999015945.SGD","SG9999001176.SGD","LU1061106388.HKD","IE0009355771.USD","LU2237443622.USD","LU2462157665.USD","LU1069344957.HKD","LU2264538146.SGD","LU2746668974.SGD","LU0786609619.USD","IE0005OL40V9.USD","LU0787776722.HKD","LU1983299246.USD","LU1868837136.USD","LU2028103732.USD","IE00B2B36J28.USD","SG9999015978.USD","LU2023250504.SGD","LU2063271972.USD","LU0158827781.USD","LU0640476718.USD","SGXZ99366536.SGD","LU0320765059.SGD","LU2471134796.USD","LU0122379950.USD","LU2471134952.CNY","IE00BFTCPJ56.SGD","LU1974910355.USD","SGXZ57979304.SGD","LU0058720904.USD","IE00BK4W5M84.HKD","LU2237443465.HKD","LU2236285917.USD","IE00BKPKM429.USD","LLII","IE00BWXC8680.SGD","SGXZ51526630.SGD","BK4139","LU2357305700.SGD","LU0385154629.USD","LU2237438978.USD","LU0882574139.USD","LU1093756325.SGD","LU2089284900.SGD","LU0158827948.USD","LU1988902786.USD","LU1280957306.USD","LU1323610961.USD","IE00BN29S564.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620403829","title":"ImageneBio grants 43,000 stock options at USD 6.20 per share under its 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403829","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403829?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:30","pubTimestamp":1773779412,"startTime":"0","endTime":"0","summary":"ImageneBio said its board compensation committee granted inducement equity awards to two newly hired employees totaling 38,442 restricted stock units and 43,000 non-qualified stock options. Each option has an exercise price of USD 6.2 per share. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. The restricted stock units vest in equal annual installments over four years, beginning after one year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL5vf4gP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4112","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","SG9999014039.USD","IMA","LU2095319765.USD","BK4007","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4585","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620038434","title":"Imagenebio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620038434","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620038434?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:30","pubTimestamp":1773779401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA9KJCLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618900220","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanobiotix (NBTX), ImageneBio (IMA) and Dianthus Therapeutics (DNTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618900220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618900220?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:20","pubTimestamp":1773296439,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nanobiotix (NBTX – Research Report), ImageneBio (I...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nanobiotix-nbtx-imagenebio-ima-and-dianthus-therapeutics-dnth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nanobiotix-nbtx-imagenebio-ima-and-dianthus-therapeutics-dnth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","IMA","NBTX","BK4588","BK4137","XBI","HCSG","DNTH","LU0029874061.USD","LU0128526141.USD","XLV","BK4007","BK4581","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618804913","title":"Legal and Regulatory Risks: How Litigation and Government Actions Could Impact Imagenebio, Inc.’s Financial Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2618804913","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618804913?lang=en_us&edition=fundamental","pubTime":"2026-03-11 14:01","pubTimestamp":1773208866,"startTime":"0","endTime":"0","summary":"Imagenebio, Inc. (IMA) has disclosed a new risk, in the Litigation & Legal Liabilities category. Imagenebio, Inc. operates in multiple heavily regu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/legal-and-regulatory-risks-how-litigation-and-government-actions-could-impact-imagenebio-inc-s-financial-performance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/legal-and-regulatory-risks-how-litigation-and-government-actions-could-impact-imagenebio-inc-s-financial-performance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618968909","title":"Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618968909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618968909?lang=en_us&edition=fundamental","pubTime":"2026-03-11 01:50","pubTimestamp":1773165009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD – Research Report) and ImageneBio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-opus-genetics-ird-imagenebio-ima-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-opus-genetics-ird-imagenebio-ima-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMA","LU0029874061.USD","IRD","BK4112","BK4007","BK4585","LU0128526141.USD","XBI","BLSX","BK4139","BLSG","BK4137","BK4588","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618693064","title":"ImageneBio Q4 EPS $(6.73) Misses $(1.44) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618693064","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618693064?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:06","pubTimestamp":1773144392,"startTime":"0","endTime":"0","summary":"ImageneBio (NASDAQ:IMA) reported quarterly losses of $(6.73) per share which missed the analyst consensus estimate of $(1.44) by 368.34 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51153905/imagenebio-q4-eps-6-73-misses-1-44-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPIQ","QQQE","TQQQ","QQQY","QQQJ","BK4007","PSQ","IMA","NVIW.SI","SQQQ","QID","USAW.SI","JEPQ","USJW.SI","QYLG","MNQmain","NQmain","TSYW.SI","QLD",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618393056","title":"ImageneBio Q4 net loss rose 44% to USD 6.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618393056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618393056?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:03","pubTimestamp":1773144196,"startTime":"0","endTime":"0","summary":"ImageneBio reported a Q4 net loss of USD 6.9 million, up 44% year over year due to additional operating costs following the merger and related transaction costs. Q4 R&D expenses were USD 3.3 million, down 13%, while G&A expenses rose more than doubled to USD 5.2 million mainly on higher merger-related professional fees and increased personnel and stock-based compensation. For FY 2025, net loss was USD 45.35 million, up 24%, and loss from operations was USD 48.45 million, up 31%. FY 2025 license revenue was USD 0.8 million, down 77%. ImageneBio ended 2025 with USD 135.3 million in cash, cash equivalents and marketable securities, and said its Phase 2b IMG-007 ADAPTIVE trial remains on track for a 2027 topline readout .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDLxSv3B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014005.SGD","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4007","LU2210149790.SGD","BK4112","SG9999014039.USD","LU2095319765.USD","BK4588","LU0314104364.USD","LU2210150020.SGD","IMA","SG9999014013.SGD","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618937022","title":"Press Release: ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937022","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937022?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 10, 2026  -- ImageneBio, Inc.   today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update.-- The IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe. atopic dermatitis  is ongoing at North American sites; the study. began enrolling in mid-2025 with topline data expected in 2027. A recent. blinded safety review showed a favorable emerging tolerability profile. -- The Company has submitted a protocol amendment intended to expand the. number and exposure range of dosing regimens being evaluated,characterize the role of loading doses, evaluate patient-friendly dosing. intervals, and understand the effect of short- and longer-term treatment. -- The Company welcomed Dr. Ben Porter-Brown, who brings deep inflammation. and medical dermatology experience including leading the development of. anti-OX40L investigational therapeutic amlitelimab through the end of. characterization of the non-depleting","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMA","AD","SID","BK4006","BK4132","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616330087","title":"ImageneBio Inc  expected to post a loss of $1.45 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330087","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330087?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:56","pubTimestamp":1772459766,"startTime":"0","endTime":"0","summary":"ImageneBio Inc  expected to post a loss of $1.45 a share - Earnings Preview ImageneBio Inc IMA.OQ IMA.O is expected to  show no change in quarterly revenue when it reports  results on March 4 (estimat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL8N3ZQ1WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IMA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}